Comparison 1. Azole versus terbinafine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical cure	15	2168	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.72, 0.95]
1.1 Short‐term follow‐up (≤ 52 weeks)	6	911	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.77, 0.96]
1.2 Long‐term follow‐up (> 52 weeks)	9	1257	Risk Ratio (M‐H, Random, 95% CI)	0.80 [0.63, 1.00]
2 Mycological cure	17	2544	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.68, 0.88]
2.1 Short‐term follow‐up (≤ 52 weeks)	8	1287	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.64, 0.93]
2.2 Long‐term follow‐up (> 52 weeks)	9	1257	Risk Ratio (M‐H, Random, 95% CI)	0.78 [0.64, 0.95]
3 Adverse events	9	1762	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.86, 1.17]
4 Recurrence rate	5	282	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.68, 1.79]